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From Bench to Bedside
Inhibitors of Protein Kinase Signaling Pathways
Emerging Therapies for Cardiovascular Disease
Thomas Force, MD; Keisuke Kuida, MD; Mark Namchuk, PhD;
Keykavous Parang, PhD; John M. Kyriakis, PhD
Abstract—Protein kinases are enzymes that covalently modify proteins by attaching phosphate groups (from ATP) to
serine, threonine, and/or tyrosine residues. In so doing, the functional properties of the protein kinase’s substrates are
modified. Protein kinases transduce signals from the cell membrane into the interior of the cell. Such signals include not
only those arising from ligand–receptor interactions but also environmental perturbations such as when the membrane
undergoes mechanical deformation (ie, cell stretch or shear stress). Ultimately, the activation of signaling pathways that
use protein kinases often culminates in the reprogramming of gene expression through the direct regulation of
transcription factors or through the regulation of mRNA stability or protein translation. Protein kinases regulate most
aspects of normal cellular function. The pathophysiological dysfunction of protein kinase signaling pathways underlies
the molecular basis of many cancers and of several manifestations of cardiovascular disease, such as hypertrophy and
other types of left ventricular remodeling, ischemia/reperfusion injury, angiogenesis, and atherogenesis. Given their
roles in such a wide variety of disease states, protein kinases are rapidly becoming extremely attractive targets for drug
discovery, probably second only to heterotrimeric G protein– coupled receptors (eg, angiotensin II). Here, we will
review the reasons for this explosion in interest in inhibitors of protein kinases and will describe the process of
identifying novel drugs directed against kinases. We will specifically focus on disease states for which drug
development has proceeded to the point of clinical or advanced preclinical studies. (Circulation. 2004;109:1196-1205.)
Key Words: drugs 䡲 kinases 䡲 pharmacology 䡲 inhibitors

A

consensus is emerging that protein kinase modulators
will be effective treatments for a variety of diseases.1
However, protein kinases were initially thought to be unsuitable drug targets, in large part because of what was perceived
to be an unfavorably high degree of structural conservation
within key domains of all protein kinases. Because binding of
ATP to kinases is essential for kinase activity and properties
of the protein kinase ATP-binding pocket were well understood, agents targeting the ATP pocket were the logical first
choice for drug development. However, the structural conservation of protein kinase ATP binding sites and the presence of more than 500 protein kinases in the human genome2
led to the belief that highly selective small-molecule protein
kinase inhibitors targeting the ATP pocket would be difficult
to generate. As will be discussed below, the development and
characterization of inhibitors of the p38 mitogen-activated
protein kinases (MAPKs) indicated that this initial belief was
misguided. A second argument against targeting protein
kinases for drug development was the observation that
modulation of a protein kinase could in one system prove

beneficial, while proving deleterious in another. As an extreme example of this, inhibiting a protein kinase required for
triggering programmed cell death could reduce ischemiainduced cell death in terminally differentiated cardiomyocytes but might also favor tumor promotion in other organs or
cell types. Finally, toxicity with long-term use was a concern.
Thus, inhibiting a protein kinase that is dysregulated in one
organ in a particular disease state may prove harmful to other
systems in which that same protein kinase is not dysregulated
but instead serves essential functions. For example, inhibiting
the cell-surface HER2 tyrosine kinase receptor with the
monoclonal antibody trastuzumab (Herceptin, Genentech) in
patients with breast cancers overexpressing that receptor has
produced strikingly beneficial results, but it has come at the
expense of severe cardiac dysfunction in some women
receiving the therapy, suggesting a critical role for this
receptor in cardiomyocyte survival.3
All of the above concerns being noted, the “proof of
principle” of the tremendous therapeutic potential of smallmolecule inhibitors of protein kinases came with the discov-

From the Molecular Cardiology Research Institute, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Mass (T.F.,
J.M.K.); Vertex Pharmaceuticals, Inc, Cambridge, Mass (K.K., M.N.); and the Department of Biomedical Sciences, University of Rhode Island, Kingston
(K.P.).
Drs Namchuck and Kuida are employees of and Dr Force receives financial support for his laboratory from Vertex Pharmaceuticals, Inc, which
produces small-molecule inhibitors of protein kinases, are the subject of this article.
Additional material may be found in the Data Supplement with the online-only version of this article at http://www.circulationaha.org.
Correspondence to Thomas Force, MD, Molecular Cardiology Research Institute, Tufts-New England Medical Center, 750 Washington St, Box 8486,
Boston, MA 02111. E-mail tforce@tufts-nemc.org
© 2004 American Heart Association, Inc.
Circulation is available at http://www.circulationaha.org

DOI: 10.1161/01.CIR.0000118538.21306.A9

1196 of Rhode Island--Kingston on March 19, 2013
Downloaded from http://circ.ahajournals.org/ at University

Force et al
ery of imatinib mesylate (Gleevec, STI-571, Novartis), an
ATP-competitive small-molecule inhibitor of the tumorigenic
fusion protein Bcr-Abl (reviewed by Barnes and Melo4)
(Table; Figure 1). c-Abl is a nuclear protein tyrosine kinase
the biological function of which is unclear (although it may
function in sensing the integrity of the genome and promoting
programmed cell death). Bcr is a multifunctional cytosolic
polypeptide that may play a role in regulating activity of the
Rho subfamily of small G proteins. The fusion of Bcr and Abl
to produce Bcr-Abl arises from the chromosomal translocation that creates the Philadelphia chromosome. Unlike c-Abl,
Bcr-Abl is both cytosolic and nuclear, and because it forms
homodimers that cross-phosphorylate and activate one another, Bcr-Abl manifests constitutively active and inappropriately directed Tyr kinase activity. Bcr-Abl is causal in
chronic myelogenous leukemia, and treatment with imatinib
has been able to induce complete remissions, at least in the
early stages of the disease.4
Indeed, the cancer field has led the way in spurring on drug
development directed both at protein kinases that, like BcrAbl, are activated by mutations and lead directly to growth
deregulation and at “permissive” protein kinases that, while
otherwise normal themselves, serve as essential effectors for
mutant, deregulated gene products. The protein kinases
MAPK ERK kinase (MEK)1/2, which activate the extracellular signal–regulated kinase (ERK) family of MAPKs (Figure 2), and the mammalian target of rapamycin (mTOR) are
2 such permissive kinases that play roles in cell cycle
progression. Inhibitors of these kinases (U0126 and
PD184352 [Figure 1] and rapamycin/sirolimus, respectively)
are in clinical trials for the treatment of a variety of tumors
(Table). In addition, rapamycin/sirolimus is currently used
with dramatic success as an immunosuppressant and an
inhibitor of in-stent restenosis.5 Early successes with agents
targeting protein kinases have led to the logical conclusion
that in the future, cancers will be defined not only by tumor
type and stage but also by the protein kinase activity profile
(ie, which kinases are dysregulated).6 It is likely that the same
will be true for complex disease states of the cardiovascular
system.

Developing an Inhibitor
A major issue in drug development is the identification of
appropriate targets for therapeutic intervention. To identify a
protein kinase as a putative therapeutic target, it is not
sufficient simply to know whether it is activated (or inhibited)
in a specific disease state, because dysregulation can be an
irrelevant consequence of the disease rather than a key
contributing factor to disease pathology. At the very least,
clear genetic or physiological/cell biological data are needed
that implicate a protein kinase as an attractive target.
Once a kinase is validated as a potential target for drug
development, screening of chemical libraries is performed to
identify possible inhibitors. Many large pharmaceutical companies possess enormous chemical libraries consisting of
hundreds of thousands of synthetic compounds. The identification of one or more of these as a candidate inhibitor
requires a process called high-throughput screening (HTS).
(For the interested reader, a more detailed description of the
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process of HTS is available on-line and in Reference 7.) A
good, robust, and reliable HTS assay can be used to screen
⬎100 000 small molecules in a day. Typical “hit rates” for an
unbiased screen might be only 0.1% to 0.3%; therefore,
various strategies have been devised to improve hit rates by
focusing the screen. Focusing of the library of compounds
can be based on the actual crystal structure of the ATPbinding pocket of the kinase or a family member if known
(structure-based library design) or on the structure of compounds already known to bind to the ATP pocket if available
(ligand-based library design). These virtual screening or
molecular modeling approaches to screen more targeted
libraries not only can improve the hit rate but also may reduce
the duration and expense of primary screens.7
Binding of ATP to a protein kinase is essential for the
kinase’s phosphotransferase activity, and thus, the ATPbinding pocket is the “target” of most inhibitor screens. As
was noted above, this idea initially seemed counterintuitive,
given the structural conservation of protein kinase ATPbinding sites.8 However, there is, in fact, enough structural
diversity in these sites8 to predict that selective ATPcompetitive inhibitors can be identified. Indeed, contrary to
initial concerns, screens of unbiased compound libraries have
identified several ATP competitors that function as relatively
selective inhibitors.9,10
For a protein kinase inhibitor to have a chance of clinical
efficacy, it must bind to the target kinase with an extremely
high affinity: several orders of magnitude higher than that of
ATP, because the inhibitor will be present in concentrations
typically in the mid to high nanomolar range, whereas the
intracellular concentration of ATP is millimolar. This suggests that any initial “hits” from an HTS will most likely
benefit from optimization to improve potency and selectivity.
The efficiency of the optimization process is greatly augmented by the abundant x-ray crystallographic information
available for kinase families. Thus, the structure–activity
relationship of any compound can be correlated with specific
molecular interactions of the compound with the kinase
active site, and in this way, the structure of the inhibitor can
be optimized.7 When no structure data exist for a specific
kinase, knowledge of the structure of another member of the
family can often be used to create binding models from which
optimized compounds can be synthesized.7
The need for an extremely high binding affinity of an
inhibitor to the ATP pocket and the relative similarities of
ATP pockets across protein kinase families suggest that it
may be beneficial to examine protein kinases for determinants in addition to the ATP pocket that might confer
additional specificity. Here, the MAPKs provide an excellent
example. The ability of different MAPK groups to interact
with and then phosphorylate selective intracellular protein
substrates is conferred by a specific substrate docking site of
the MAPKs, the common docking (CD) domain, that is quite
distal from the ATP binding site.11 The CD motifs of MAPKs
bind complementary sites on the corresponding MAPK substrates (and on MAPK regulators) (eg, MEK1 binding to
ERK-1 [Figure 2] is mediated by the CD domain). Although
there is substantial sequence conservation among MAPK CD
domains, the sequence divergence is sufficient to enable
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Selected Inhibitors of Protein Kinases in Clinical Trials
Kinase Target
Tyrosine kinases
ABL (c-Kit, PDGFR)
EGFR

EGFR, ERB2R

VEGFR (PDGFR, FGFR)
PDGFR (Flt-3)
VEGFR
VEGFR (EGFR)
VEGFR (PDGFR)
NGFR, Trk
HER-2/neu

Serine/threonine kinases
PKC, c-Kit, PDGFR
PKC

PKC-␤
CDKs

MEK1/2
MLK
RAF

Ras

mTOR

p38-MAPK

PDK1
JNK1–3

Agent

Trial (Disease)

Sponsor

Gleevec (STI-571)
ZD1839 (Iressa)
OSI-774
IMC-C225 (mAb)
ABX-EGF (mAb)
MDX-447 (mAb)
EMD 72000 (mAb)
Genistein
RH3 (mAb)
CI1033
EKB569
GW2016
PKI166
SU6668
CT53518
SU5416
PTK787/ZK222584
ZD6474
SU011248
CEP-2583
17-AAG
Trastuzumab (mAb)
2C4 (mAb)
CP-724,714
MDX-210 (mAb)

Approved (CML)
Approved (lung cancer)
Phase III (cancer)
Phase III (cancer)
Phase II (cancer)
Phase I (cancer)
Phase I (cancer)
Phase II (cancer)
Phase II (cancer)
Phase II (cancer)
Phase I (cancer)
Phase I (cancer)
Phase I (cancer)
Phase I (cancer)
Phase I (cancer)
Phase III (cancer)
Phase II (cancer)
Phase II (cancer)
Phase II (cancer)
Phase II (cancer)
Phase I (cancer)
Approved (cancer)
Phase I (cancer)
Phase I (cancer)
Phase I (cancer)

Novartis
AstraZeneca
OSI/Roche/Genentech
ImClone
Abgenix
Merck KgaA
Merck KgaA
NCI
York Medical Bioscience Inc
Pfizer
Wyeth-Ayerst
GlaxoSmithKline
Novartis
Pharmacia Corp
Millennium Pharmaceuticals
Pharmacia Corp
Novartis/Schering-Plough
AstraZeneca
Sugen
Cephalon
Kosan
Genetech
Genetech
OSI Pharmaceuticals/Pfizer
Novartis

PKC412
ISIS 3521
CGP41251
UCN-01
Bryostatin-1
Ly333531

Phase II (cancer, retinopathy)
Phase III (cancer)
Phase II (cancer)
Phase I/II (cancer)
Phase I/II (cancer)
Phase I (cancer)
Phase II/III (diabetic neuropathy)
Phase II (cancer)
Phase I (cancer)
Phase I (cancer)
Phase I (cancer)
Phase II (cancer)
Phase I (cancer)
Phase II (neurodegeneration)
Phase II (cancer)
Phase II (cancer)
Phase II (cancer)
Phase II (cancer)
Phase II (cancer)
Phase I (cancer)
Phase I/II (cancer)
Phase II (cancer)
Phase I (cancer)
Phase II/II (immunosuppressant)
Approved (immunosuppressant)
Phase II (inflammation; ACS)
Phase III (inflammation; RA; Crohn’s)
Phase I (RA; stroke; diabetes)
Phase II (RA; Crohn’s)
Phase I/II (cancer)
Phase I

Novartis
ISIS Pharmaceuticals
Novartis
Kyowa Hakko Kogyo
Biotek
Eli Lilly

Flavopiridol
E7070
BMS-387032
CYC202
PD184352
U-0126
CEP-1347
BAY43–9006
ISIS5132
L-779,450
ISIS2503
SCH66336
BMS214662
R115777
CCI779
RAD001
Rapamycin
VX702
BIRB796
SCIO-323
SCIO-469
UCN-01
CC401

Aventis
EISAI
Bristol-Myers Squibb
Cyclacel
Pfizer
Promega
Cephalon
Onyx Pharmaceuticals/Bayer
Isis pharmaceuticals
Merck
Isis pharmaceuticals
Schering-Plough
Bristol-Myers Squibb
Johnson & Johnson
Wyeth-Ayerst
Novartis
Wyeth-Ayerst
Vertex Pharmaceuticals
Boehringer Ingelheim
Scios, Inc
Scios, Inc
Kyowa Hakko Kogyo
Celgene

VEGFR indicates vascular endothelial growth factor receptor; PDGFR, PDGF receptor; FGFR, fibroblast growth factor receptor; CML, chronic
myelogenous leukemia; RA, rheumatoid arthritis; and ACS, acute coronary syndromes. Inhibitors are of two types, monoclonal antibodies (mAbs),
which are directed at the extracellular domain of various receptor tyrosine kinases, and small-molecule inhibitors.
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Figure 1. Chemical structures of several smallmolecule protein kinase inhibitors referred to in
text. These can be divided into inhibitors that are
ATP-competitive, including phenylamino pyrimidines (eg, STI-571), pyridinylimidazoles
(SB202190, SB203580, and SB239063), anthrapyrazolones (SP600125), and maleimides
(SB415286), and those that are non–ATPcompetitive (MEK1/2 inhibitors, U0126, PD184352,
and PD98059, which maintain kinases in an inactive state by preventing their phosphorylation by
upstream activating kinases such as Raf).
BIRB796, a pyrazole urea, is both noncompetitive
and competitive (see text).

exquisite MAPK specificity. Of note, the CD domains are
quite small (ⱕ18 amino acids), contain key acidic residues,
and reside on an exposed surface in the MAPK structure,
suggesting that these domains could be ideal targets for drug
design.11
The use of determinants in addition to the ATP pocket
combined with optimization based on crystal structure was
recently used to optimize the design of a p38-MAPK inhibitor. Crystallography demonstrated that this inhibitor did not
target the ATP binding pocket but rather targeted a novel site
in the kinase active site that is exposed after a large
conformational change that accompanies binding of the
inhibitor.12 Crystallography allowed the compound to be
modified to optimize binding to the novel site and also to
establish binding in the ATP pocket. This gives the final
compound, BIRB796 (Figures 1 and 3), which is currently in
clinical trials for various inflammatory disorders (Table), a
high degree of potency and selectivity.
Another approach to inhibit MAPK signaling that might
reduce toxicity would be to target upstream activators of the
MAPKs rather than the MAPKs.13 For example, c-Jun
N-terminal kinase (JNKs) are activated by at least 12 different

MAPK kinase kinases (MAPKKKs) and 2 MAPK kinases
(MAPKKs: see legend to Figure 2 for terminology). Because
specific MAPKKKs and MAPKKs transduce the activation
of JNKs in response to specific stimuli14 (eg, MAPKK7 but
not MAPKK4 is necessary for JNK activation by tumor
necrosis factor [TNF]-␣), one could potentially target
MAPKK7 specifically with an inhibitor in patients with
inflammatory disorders. This would leave JNK activation by
other stimuli acting via MAPKK4, and essential cellular
functions regulated by JNKs, at least partially intact.

Potency and Selectivity
Potency and selectivity are critical issues for the eventual
effectiveness and safety of any drug. Potency is expressed as
the enzymatic IC50 (concentration of drug that inhibits enzyme activity by 50%). However, reported IC50s must be
interpreted with caution, because the IC50 determined for an
ATP-competitive inhibitor will vary depending on the concentration of ATP used in the assay and on the Km (the
affinity of the kinase for ATP).10 This has been a source of
significant confusion in the literature. For example, results
from assays of the widely used anthrapyrazolone JNK inhib-
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Figure 2. ERK cascade. All MAPKs described to date are
part of a 3-tiered cascade whereby MAPKs, in this case,
ERKs, are activated by upstream kinases (MAPKKs, in this
case MEK1/2), which, in turn, are activated by a MAPKKK (in
this case Raf-1). Growth factor–induced activation of pathway
often leads to cell cycle progression and, in some cases,
activation of survival pathways. I/R in brain also leads to ERK
activation, but in this case it is deleterious, leading to neuronal death. It is not clear whether Raf-1 is the MAPKKK
involved in I/R-induced activation of ERKs in brain. MEK inhibitors discussed in text are shown.

itor SP600125 (Figure 1) with 20 mol/L ATP initially
suggested that SP600125 was a very potent inhibitor with a
low IC50. However, the results of studies that used assays with
more “physiological” concentrations of ATP (100 mol/L)
recently demonstrated that SP600125 was, in fact, a relatively
weak (and also nonselective) inhibitor with a high IC50.10
Selectivity is a second key consideration in the design of
kinase inhibitors. Compounds are “profiled” for their selectivity against panels of kinases (often 30 or more) to determine which targets, aside from the intended one, are being
affected. These panels are chosen in a variety of ways but
often include specific kinases that one does not want the drug
to inhibit and/or a selection of kinases with a great deal of
structural diversity at the active site (to broadly screen for
nonspecific inhibition). Relative IC50s of the drug for the

Figure 3. Mechanisms of p38-MAPK–induced cardiomyocyte
death. I/R activates p38-MAPK, leading to both cytokine (and
chemokine) production and upregulation of adhesion molecules
on endothelial cells. This leads to leukocyte infiltration into ischemic region. Certain cytokines (eg, TNF-␣) are directly cytotoxic to cardiomyocytes. In addition, p38-MAPK probably also
directly activates cell death pathways in ischemic cardiomyocytes (ie, cytokine- and leukocyte-independent effects on cell
death). p38-MAPK inhibitors discussed in text are shown. Of
note, JNKs also act to stabilize cytokine mRNA and, in addition,
activate intrinsic cell death pathway by inducing release of cytochrome c from mitochondria.36 This suggests that JNK inhibitors
may also be protective against I/R injury (see text).

target kinase versus the others in the panel are then determined. Again, the concentration of ATP used in the assay is
critical to allow an accurate comparison to be made. One
approach to allow interpretation of relative IC50s for an
inhibitor between enzymes is to customize the assay conditions for the ATP affinity for each kinase in the screening
panel (eg, fix the ATP concentration at the Km for each
kinase). Alternatively, others recommend using concentrations of ATP, ⱖ100 mol/L, that are well above the Km for all
of the kinases in the panel.10
What is an acceptable level of selectivity? There is no
consensus, but in general, the goal is an IC50 that is at least
100-fold lower for the target kinase. However, this may vary
depending on the indication, and in some cases, one might
tolerate (or even prefer) agents that are not entirely selective.
For example, in cancer, one might tolerate inhibition of
kinases that positively regulate the cell cycle (cyclindependent kinases, Cdks) or that are antiapoptotic (eg, Akt)
by a drug targeting Bcr-Abl, because antitumor activity might
be greater. However, because of enhanced toxicity, one
would not tolerate inhibition of Cdks or Akt by a drug
targeting p38-MAPK for inflammatory diseases. Similarly,
lack of selectivity for drugs that will be used short-term only
might not be a major problem.
Once selectivity is determined in kinase assays in vitro,
the selectivity profile is then determined in a cellular
system. Given that cellular ATP concentrations are typically in the millimolar range, an upward shift in the
cellular IC50 versus the enzymatic IC50 (performed at 100
mol/L or less) is often observed. The magnitude of this
shift is dictated by a number of factors, including the ATP
Km for the target enzyme, the cellular permeability of the
drug, and the amount of inhibition of the target kinase
required to elicit the cellular response being monitored (eg,
20% inhibition of a particular kinase may be sufficient to
lead to complete inhibition of a biological response). An
effective general counterscreening strategy is to obtain
enzymatic IC50 values for an extensive panel of biochemical kinase assays, then assess the cellular consequences of
the observed inhibition pattern in cellular readouts biased
to respond to inhibition of the signaling pathways represented in the enzymatic panel. If a drug with borderline
selectivity in enzymatic assays has excellent characteristics in the cell-based assays (good inhibition of the target
pathway, limited inhibition of other pathways, and no
toxicity), the borderline enzymatic selectivity may be
deemed adequate.
Finally, although the IC50 and selectivity studies (determined in assays in vitro) usually predict activity in the cell,
this is not always the case. Thus, a compound with apparent
high activity and specificity in vitro may display markedly
different and even unexpectedly nonspecific activity in vivo.
For example, the pyridinyl imidazoles SB203580 and
SB202190 (Figure 1), which inhibit p38 MAPKs, are remarkably specific when assayed in vitro for inhibition of a variety
of protein kinases.9 The basis for this specificity was revealed
in the crystal structure of p38␣ complexed with SB203580.
To accommodate a fluorophenyl moiety present in the
SB203580 structure, the amino acid at position 106 of the
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kinase must be no larger than Thr.15 c-Raf, a protein kinase
that activates the ERKs, is downstream of many growth factor
receptors and plays a role in inducing cell-cycle progression
(Figure 2), has a Thr (Thr321) at a site corresponding to
Thr106 of p38␣. Not unexpectedly, therefore, c-Raf is inhibited by SB203580 and SB202092 in vitro, albeit at concentrations at least an order of magnitude higher than that needed
to inhibit p38␣.13,14 However, in cell-based assays, the
Raf–Mek-ERK pathway is not inhibited by SB203580 or
SB202092. Surprisingly, SB203580 and SB202092 trigger a
striking activation of c-Raf in vivo.16 Similarly, ZM336372
(Figure 1), a novel phenylamido derivative, is an in vitro Raf
(and p38-MAPK) inhibitor but is a potent activator of c-Raf
in intact cells. The basis for these paradoxical findings is
unknown, but they are indicative of the fact that assertions as
to the specificity of a compound in vitro require rigorous and
comprehensive testing in cellular and whole-animal systems.

To the Bedside
The Table is a listing of most of the protein kinase inhibitors
currently in clinical trials and the diseases targeted. As can be
seen, most are cancer trials, but there is a trend toward
targeting protein kinases for the treatment of a number of
chronic conditions other than cancer, including inflammatory
and cardiovascular diseases. Indeed, several of the agents
listed in the Table have strong preclinical data suggesting that
they may be efficacious in the therapy of patients with a
variety of cardiovascular diseases. The list of potential
protein kinase targets for cardiovascular therapies is extensive. However, rather than a summary of disease states and
protein kinases possibly involved (an excellent review taking
this approach for heart failure was recently published17), we
will discuss a few disease states for which inhibitors exist that
are either already in the earliest stages of clinical trials or are
in the late stages of preclinical development. These examples,
we hope, will illustrate that what was once perceived to be
impractical now seems reasonable and attainable.
Acute Coronary Syndromes
Two families of stress-activated MAPKs, the JNKs and
p38-MAPKs, are activated by ischemia/reperfusion (I/R),14,18
and there is some indication that inhibition of either the JNKs
or p38s might prove beneficial for treating acute coronary
syndromes (ACS). However, validating these MAPKs as
targets in ACS, that is, whether activation of the kinases is
beneficial or detrimental, has been difficult.19 This is because
of the lack of good genetic models (ie, mice deleted for the
gene) and, until recently for p38, good inhibitors with which
to address the question in vivo. Two members of the p38
MAPK family, p38␣ and p38␤, are activated by ischemia.
The first effective inhibitor of p38␣/␤ was discovered by Lee
and coworkers20 at SKF in a broad-based screen for “cytokine-suppressive antiinflammatory drugs” based on their
ability to inhibit endotoxin-induced cytokine production by
macrophages in culture. The target of this drug was later
identified to be the p38s. Because it seems clear that the first
wave of drugs targeting kinase pathways to be used in
patients will be dominated by p38-MAPK inhibitors, we will
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describe these kinases and the mechanisms by which the
inhibitors work in some detail.
Preventing the release of inflammatory cytokines and
chemokines represents a potentially promising approach to
treating ACS (Figure 3) and, possibly, the development and
progression of atherosclerotic plaques. Indeed, a p38 inhibitor, VX702, is currently in a phase II clinical trial in patients
presenting with ACS. The half-life of the mRNA for many
cytokines (and growth factors) is extremely short, allowing
for rapid downregulation of expression when the inciting
stimulus is removed. This short half-life is largely a result of
the presence of AU-rich elements (AREs, consisting of
several copies of the sequence AUUUA) in the 3⬘untranslated region of the mRNA.21 ARE-binding proteins
(ARE-BPs) bind to the AREs, and most ARE-BPs target
mRNA for degradation. When activated, p38s phosphorylate
ARE-BPs, inhibiting their activity.21 The end result is p38dependent stabilization of the cytokine mRNA, leading to
increased production of the cytokine protein and activation of
inflammatory cells and of endothelial cells, the latter leading
to upregulation of adhesion molecules. Thus, p38 inhibitors
block phosphorylation of the ARE-BPs, leading to degradation of the cytokine mRNAs, including those coding for
TNF-␣, interleukin (IL)-1␣/␤, IL-6, IL-10, interferon
(IFN)-␥, MIP1␣/␤, and IL-8. Although stabilization of cytokine mRNA has obviously been an important response to
infection over millions of years of evolution, inappropriate
activation of inflammatory responses has, over the past 100
years, become a significant factor driving the explosion in the
prevalence of a number of chronic disease states.
Several companies have developed p38 inhibitors, and
some of these have demonstrated efficacy in models of
inflammatory diseases, including inflammatory arthritides
and inflammatory bowel disease, as well as in endotoxemia.22,23 Some of these inhibitors are currently in clinical
trials for rheumatoid arthritis and Crohn’s disease (Table).
With the rationales that (1) ACSs, including myocardial
infarction, had prominent inflammatory components and (2)
p38 activation in ischemic tissue might, independent of
effects on inflammatory responses, have detrimental effects
on cardiomyocyte survival (see Reference 17 and references
therein), the efficacy of these drugs was tested in animal
models of acute myocardial infarction.
Early-generation p38 inhibitors, SB203580 and SB242710,
reduced I/R-induced apoptosis and preserved cardiac function
in a Langendorff-perfused rabbit heart model (reviewed in
Reference 20). Because with this model, the heart is perfused
with a buffer and therefore there are no leukocytes in the
perfusate, the findings suggest that p38 inhibition has beneficial effects directly on the myocardium, in addition to its
known effects on leukocyte recruitment and activation (Figure 3). This leukocyte-independent protective effect of p38
inhibition on the myocardium probably involves inhibition of
I/R-induced production of cytotoxic cytokines by the heart
and inhibition of p38-dependent proapoptotic pathways in
cardiomyocytes. More recently, a newer-generation p38 inhibitor, SB23906324 (Figure 1), that can readily be used in
vivo has demonstrated beneficial effects in the intact rat
model of I/R injury. In addition to direct protective effects of
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p38 on cardiomyocyte survival, SB239063 produced a dramatic reduction in the myocardial inflammatory response, as
evidenced by reduced upregulation of P-selectin and intercellular adhesion molecule and reduced neutrophil accumulation
within the ischemic zone. Other related potential applications
of p38 inhibitors include preservation of mechanical function
of cold-stored hearts before transplantation.25 This effect of
p38 inhibition may be, in part, related to increased contractility caused by enhanced myofilament responsiveness to
calcium.26
There are other potential applications for these cytokinesuppressive drugs, including the treatment of patients with
heart failure. Although the RENEWAL and ATTACH trials,27 targeting TNF-␣ by “capturing” it with a monoclonal
antibody or a soluble receptor, produced negative results and
raised concerns over worsening of heart failure, this of course
does not necessarily mean that the concept of anticytokine
therapies in heart failure is invalid, and it is conceivable that
more broad-based anticytokine therapy, such as one achieves
with p38 inhibitors, could be beneficial. Furthermore, we
could benefit from the experiences of the oncologists that
demonstrate that one may need to define the molecular
phenotype or kinase activity profile of the individual patient,
because just as with cancer, patients with the clinical diagnosis of “heart failure” are bound to have very different
profiles (as evidenced by the lack of consensus on the
signaling abnormalities present in the failing heart17). Although it is difficult, failing to do so may lead to discarding
agents that are effective in subsets of patients. As an example,
trastuzumab, the anti-HER2 tyrosine kinase receptor antibody, which confers a 22.5% improvement in overall survival
in breast cancer patients with tumors that overexpress HER2
(25% to 30% of all breast cancers), would have been found to
be of no value if it had been initially tested in breast cancer
patients irrespective of the HER2 status.6
Other potential concerns with anticytokine therapies include a possible increased risk of infection, including reactivation of tuberculosis, and the development of opportunistic
infections that have been seen with the anti-TNF therapies
and with anakinra, an IL-1 receptor antagonist.28 Of course,
whether these issues are specific to the anti-TNF and anti–
IL-1 therapies used or will be a general feature of all
anticytokine therapies remains to be determined.
Stroke
Inhibition of several protein kinase pathways has been shown
to be beneficial in animal models of stroke. These include the
3 families of MAPKs, the ERKs, JNKs, and p38 MAPKs.14 In
addition, cell culture studies suggest that inhibitors of glycogen synthase kinase-3 (GSK-3) may also be protective.29,30
The first reports of neuroprotection in vivo with a kinase
inhibitor used direct injection into the cerebral ventricles of
PD98059 (Figures 1 and 2), a first-generation inhibitor of the
activation of MEK1/29 (Figure 2 legend), the kinases that
activate the ERKs.31 This was followed by studies with
intravenous administration of another MEK1/2 inhibitor,
U0126 (currently in clinical trials for cancer; Table), which
was also protective against forebrain and focal cerebral
ischemia.32 Remarkably, beneficial effects were seen with

administration after 3 hours of ischemia, before reperfusion.
These studies seemed counterintuitive, because the ERKs had
generally been thought to be antiapoptotic in most settings
(Figure 2), including in I/R injury in the heart.19 The
mechanism of protection may be prevention of excitotoxicity,33 which is neuronal death caused by release of excitatory
amino acids that activate metabotropic glutamate receptors.
Excitotoxicity plays a critical role in I/R injury in the brain,
and although the precise mechanisms of protection remain to
be determined, MEK1/2 inhibitors may be blocking release of
glutamate. In addition to stroke, MEK1/2 inhibitors have
been reported to be protective against traumatic brain injury.34 As one caveat, PD98059 and U0126 also block activation of MEK5,9 the kinase that activates ERK5, the sole
member of the fourth MAPK family. Thus, one cannot at this
time formally rule out MEK5/ERK5 as the relevant target.
Strikingly, another MEK1/2 inhibitor, PD184352, has been
reasonably well tolerated when administered orally, twice
daily, for 21 days (repeating every 4 weeks) in a phase I
dose-ranging trial in cancer patients, with only fatigue, rash,
and diarrhea being commonly reported.6
Inactivation of JNK3 (via gene deletion in a knockout
mouse), which is selectively expressed in the central nervous
system, and inhibition of p38 activation (by SB239063) were
also protective in stroke models.35,36 In the latter case,
SB239063 reduced stroke-induced expression of TNF-␣ and
IL-1␤, cytokines that are believed to enhance neuronal loss
after I/R. No fewer than 8 companies have reported the
development of JNK inhibitors, many focusing on JNK3 and
neuroprotection (stroke and neurodegenerative disorders).37
Some have reported enhanced cell survival in a stroke
model.37 Safety studies with one agent (CC401, Table) are
ongoing in healthy volunteers.37
Inhibitors of GSK-3 are being proposed as potential therapies for disorders as diverse as bipolar mood disorders
(lithium and valproic acid are GSK-3 inhibitors), Alzheimer’s
disease (in which GSK-3 is believed to play a key role in
formation of the neurofibrillary tangles and amyloid plaques,
the latter being reduced by lithium in an animal model of
Alzheimer’s disease38), and stroke.30 GSK-3 is inhibited
when phosphorylated by the antiapoptotic kinase Akt, and at
least part of the antiapoptotic effects of Akt are believed to be
mediated by inhibition of GSK-3. GSK-3 inhibition may also
mediate part of the phenomenon of ischemic preconditioning.39 Published data are limited, but at this point, selective
inhibitors (SB216763 and SB415286; Figure 1) have been
shown to block neuronal cell death in culture induced by
pharmacological inhibition of the PI3-kinase/Akt pathway or
by polyglutamine toxicity caused by the Huntington’s disease
mutation.29,40 Although promising, this kinase is a critical
regulator of many basic cellular processes, including development, cardiac growth and hypertrophy, and tumorigenesis.41,42 Therefore, it is likely that in the near future, inhibitors
of GSK-3 will be restricted to relatively short-term use in
high-risk patients.
Hypertension
Rho belongs to a family of small GTP-binding proteins that
mediate intracellular signaling induced by activation of het-
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erotrimeric G protein– coupled receptors and growth factor
receptors. In the cardiovascular system, Rho regulates vascular smooth muscle contraction by modulating sensitivity to
Ca2⫹. One Rho effector is Rho kinase (ROCK), of which 2
isoforms have been identified. ROCKs phosphorylate the
myosin-binding subunit of myosin light chain phosphatase
and LIM kinase, ultimately regulating phosphorylation of
myosin light chain and, via this mechanism, vascular smooth
muscle cell contraction.43 Therefore, it is tempting to speculate that ROCK inhibition could enhance coronary vasodilatation by changing Ca2⫹ sensitivity of coronary artery smooth
muscle cells. In fact, a ROCK inhibitor, hydroxyfasudil,
suppresses myosin light chain phosphorylation and significantly inhibits coronary spasm in a pig model. Two recent
clinical trials of fasudil indicate that it may be an effective
and well-tolerated antianginal agent44 and also may be of
benefit in patients with microvascular spasm of the coronary
arteries.45 Although the selectivity of fasudil against ROCKs
is in question, these results suggest a potential use of ROCK
inhibitors as novel agents to treat symptomatic patients with
CAD. Another relatively specific ROCK inhibitor, Y-27632
(Figure 1),9 is effective in lowering systolic blood pressure in
spontaneously hypertensive rats, DOCA-salt rats, and renal
hypertensive rats without affecting blood pressure in normal
rats.43 Collectively, selective ROCK inhibitors will probably
be a novel approach to the treatment of hypertension. However, Y-27632 has also been shown to affect metastasis,
neurite outgrowth, and contraction of smooth muscle cells
other than vascular smooth muscle cells.43 Therefore, the
safety of Y-27632 and related agents remains a question and
will need to be carefully evaluated in clinical trials.
Given the difficulty in controlling hypertension in elderly
patients and diabetics, there will probably be many more
targets against which inhibitors will be made. These could
include the WNK (with no lysine) family of kinases, mutations of which are responsible for a rare hereditary form of
hypertension, pseudohypoaldosteronism type II.46 Because
the WNK4 gene lies close to a locus showing the strongest
linkage to blood pressure variation in the Framingham Heart
Study, less severe mutations and polymorphisms of the WNK
genes may play a more general role in hypertension. If so,
these kinases might be ideal targets.
Diabetes and the Metabolic Syndrome
Another avenue open to manipulating activity of protein
kinases is to identify drugs that activate, as opposed to
inhibiting, a kinase. Protein kinases that are beneficially
activated by allosteric mechanisms represent attractive targets
for such therapies. One of these is the 5⬘-AMP-activated
protein kinase (AMPK). AMPK exists in the cell as a
heterotrimer of ␣, ␤, and ␥ subunits (the ␣ subunit containing
the kinase domain). Genetic mutations in the human ␥2
subunit of AMPK have been linked to hypertrophic cardiomyopathy and to ventricular preexcitation.47 Specifically,
these mutations are associated with a metabolic storage
disorder marked by the accumulation of excess glycogen
granules in the myocardium. Although the mechanisms by
which these mutations lead to cardiomyopathy and preexcitation are not entirely clear, the mutations appear to inhibit
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activation of AMPK by AMP. Because AMPK inhibits
glycogen synthase, the mutation could lead to increased
glycogen synthase activity, increased glycogen production,
and the observed accumulation of glycogen in the heart.
The reason that AMPK has generated a tremendous
amount of interest on the part of pharmaceutical companies,
however, is that activators of it could be useful in the
treatment of patients with metabolic syndrome, diabetes, or
hyperlipidemia.48 AMPK was initially discovered in the early
1970s as an AMP-dependent kinase that inactivated HMGCoA reductase and acetyl-CoA carboxylase (ACC).49 It has
since been established that AMPK functions as a cellular
“fuel sensor” that is activated in times of reduced energy
availability (when [AMP] is relatively high) and serves to
inhibit anabolic processes (lipogenesis) and enhance glucose
uptake.49
Several compelling lines of evidence point to the potential
of AMPK as a useful drug target. ACC, the rate-limiting
enzyme in fatty acid synthesis, catalyzes the formation of
malonyl-CoA, a potent inhibitor of fatty acid oxidation. By
inhibiting ACC, AMPK elevates fat oxidation.49 In addition,
AMPK activation leads to reduced levels of hepatic sterol
response element– binding protein-1 and consequently suppresses the expression of several lipogenic genes. Thus,
therapeutic activators of AMPK could reduce serum triglycerides. As an inhibitor of HMG-CoA reductase, the ratelimiting enzyme in cholesterol biosynthesis, AMPK also
functions to block cholesterol production,49 and therapeutic
AMPK activators could serve in a manner similar to the
statins. In addition, AMPK is activated in exercise, triggering
skeletal muscle glucose uptake in an insulin-independent
manner. Of particular note, pharmacological activation of
AMPK with 5-aminoimidazole-4-carboxamide 1- ␤ - D ribofuranoside (AICAR) mimics exercise and triggers
insulin-independent skeletal muscle glucose uptake. Thus,
AMPK activators could also alleviate glucose intolerance. In
support of this, the biguanide antidiabetic metformin may
exert its effects in part by activating AMPK.48
The ability to activate AMPK in vitro with AMP and in
vivo with AICAR (which is phosphorylated in the cell to
ZMP, an analogue of AMP) and the observed antilipogenic
and glucose transport effects of AICAR indicate that drugs
targeting AMPK will need to be AMPK activators. It is likely
that AMP-like compounds will provide the richest source of
potential AMPK pharmaceuticals. Identification of such compounds will be assisted by the elucidation of the structural
features of the AMPK AMP-binding pocket.

Conclusions
It is very likely that the next several years of translational
cardiovascular research will feature a number of clinical trials
using inhibitors of protein kinase signaling pathways to treat
a variety of disorders. We have touched on some of the
targets for which development of inhibitors is more advanced,
but there are many others with great potential, including the
␤-adrenergic receptor kinase (heart failure)50 and some kinase
inhibitors that are currently in clinical trials for cancer and are
in the discovery phase for atherosclerosis and restenosis (eg,
growth factor receptors, including the platelet-derived growth
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factor receptor, cell cycle regulators such as Cdk-1/-2, and
protein kinase C) and for stroke (eg, Cdks).51 Toxicity
remains a major concern, because many of these kinases not
only play roles in the pathogenesis of diseases but also
function in pathways that regulate the most basic of normal
cellular processes. That said, preclinical data have been
reassuring. Toxicity data from clinical trials of these agents in
cancer will be illustrative, but many of these studies have
been designed to identify, or have used, the “maximum
tolerated dose,” which may be significantly higher than the
doses that will be used in cardiovascular diseases. The use of
combination therapy, targeting 2 or more kinases on the same
or parallel pathways, may allow the use of lower (and
therefore less toxic) doses and has shown some promise in
cancer trials.6 However, the majority of early trials will focus
on individual kinases and their role in diseases for which only
short-term therapy will be needed (eg, ACS or stroke) or for
which targeted local delivery is possible. It must be realized,
however, that these may not necessarily be the disease states
most likely to benefit from therapy. Finally, as highlighted
above, given the vast numbers of protein kinases in the
human genome and their sequence and structural similarities,
added to the inability to test the drugs against all kinases,
specificity will remain a concern with these agents. Despite
these obstacles, this new class of agents offers a great deal of
promise to expand our therapeutic options for a wide variety
of cardiovascular diseases.
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